FDA Declines Approval of Grace Therapeutics' Stroke Drug GTx-104

On April 23, 2026, the U.S. Food and Drug Administration (FDA) declined to approve Grace Therapeutics' drug GTx-104, intended for the treatment of aneurysmal subarachnoid hemorrhage, a severe type of stroke. The FDA's complete response letter highlighted deficiencies in the chemistry, manufacturing, and controls (CMC) as well as non-clinical data related to the drug's application. Following the announcement, shares of Grace Therapeutics, based in Princeton, New Jersey, fell by 43%.

Reuters

The FDA's concerns focused on several key areas. These included issues with leachables data, which pertains to chemical compounds that can migrate from packaging or manufacturing equipment into the drug. Additionally, the FDA pointed out deficiencies in non-clinical product toxicology risk assessments and manufacturing issues at the contract manufacturing organization. Grace Therapeutics acknowledged these deficiencies and expressed its intention to address them in a future resubmission.

Reuters

GTx-104 is an injectable formulation of nimodipine, the only FDA-approved drug for treating aneurysmal subarachnoid hemorrhage, which accounts for approximately 5% of all strokes in the U.S., affecting an estimated 42,500 patients annually. The injectable form aims to reduce drug-to-drug interactions and minimize dosing errors associated with intravenous administration.

Reuters

Grace Therapeutics stated that it plans to request a meeting with the FDA to clarify the necessary steps for resubmission. The company remains committed to addressing the FDA's concerns and advancing the development of GTx-104.

Reuters

While the FDA's decision is based on specific deficiencies, some industry analysts have expressed concern over the implications for Grace Therapeutics' future. The significant drop in stock price following the announcement reflects investor apprehension regarding the company's ability to navigate the regulatory landscape effectively.

Reuters

Moving forward, Grace Therapeutics aims to engage with the FDA to understand the requirements for resubmission. The company is focused on resolving the highlighted deficiencies to potentially bring GTx-104 to market, which could provide a new treatment option for patients suffering from a critical and often fatal form of stroke.

Reuters

“The company said it intends to request a meeting with the FDA to clarify the path forward and determine the appropriate next steps.” — Grace Therapeutics

Reuters